Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RVU.WA
Strong SellSinkerRyvu Therapeutics S.A. · Healthcare · Poland · $113M · Avg Vol: $211K/d
COMPANY DESCRIPTION
Ryvu Therapeutics S.A. is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies in oncology. The company's competitive moat is built on its proprietary drug discovery platform and strategic partnerships with global pharma companies like BioNTech and Exelixis. It is a leading Polish biotech innovator with a pipeline of first-in-class cancer treatments.
FINANCIAL SUMMARY (PLN)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38.9M | 46.9M | 78.0M | 62.3M | 16.9% | 88.4M | 96.9M | 58.9M | -2.7% |
| EPS (PLN) | -4.60 | -4.00 | -4.80 | -4.40 | — | -3.80 | -2.06 | -2.25 | — |
| Shares | 18.4M | 23.1M | 23.1M | 23.1M | +26.0% | 23.1M | — | — | — |
| Debt | 2.8M | 0.9M | 67.1M | 71.7M | 195.9% | 96.0M | — | — | — |
| Equity | 343.4M | 259.6M | 152.3M | 53.8M | -46.1% | — | — | — | — |
| Op CF | 21.3M | -84.5M | -129.5M | -114.1M | — | -92.8M | — | — | — |
| Inv CF | 0.7M | -195.5M | 137.2M | 17.2M | — | — | — | — | — |
| Fin CF | -2.5M | 240.8M | 94.2M | -3.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RVU.WA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RVU.WA | Ryvu Therapeutics S.A.(you) | $113M | 4 | Strong Sell |
| CTX.WA | Captor Therapeutics Spolka Akcyjna | $120M | 6 | Strong Sell |
| S2B.WA | Syn2bio S.A. | $148M | 3 | Strong Sell |
| BCX.WA | Bioceltix S.A. | $118M | 18 | Strong Sell |
| SVE.WA | Synthaverse S.A. | $46M | 11 | Strong Sell |
| MAB.WA | Mabion S.A. | $34M | 10 | Strong Sell |
| MOC.WA | Molecure S.A. | $40M | 14 | Strong Sell |
| PTG.WA | Poltreg S.A. | $34M | 13 | Strong Sell |
| NNG.WA | NanoGroup S.A. | $28M | 14 | Strong Sell |
| URT.WA | Urteste S.A. | $18M | 12 | Strong Sell |
Peer medians: ROE -16.3% · P/E 17.0x · Gross margin 30.1%